Lumenis

Lumenis is a medical laser and energy-based device company headquartered in Yokneam, Israel, with a significant commercial presence in the United States. The company develops and manufactures systems that use laser, intense pulsed light (IPL), and radiofrequency energy for medical and aesthetic applications. Lumenis has gone through multiple ownership changes over its history: it was taken private by XIO Group, a Chinese private equity firm, in 2015, and subsequently acquired by Bain Capital in 2021.

Lumenis focuses on two primary clinical domains: surgical and ophthalmology applications, and aesthetic and dermatology applications. Its surgical systems are used in urology (notably for laser lithotripsy, the fragmentation of kidney stones), ear-nose-throat procedures, and gynecology. Its ophthalmology line includes laser systems for retinal and glaucoma treatments. On the aesthetic side, its platforms address hair removal, skin resurfacing, pigmentation, and body contouring, sold into dermatology clinics and medical spas globally. The company sells through a direct sales force and distribution partners depending on geography.

Lumenis's best-known product families include the Holmium laser systems used in urology (the Moses technology platform, which modulates pulse delivery for more efficient stone fragmentation, is a named differentiator), the CO2 fractional laser platform ACUPULSE and the ResurFX module for non-ablative skin resurfacing. The SPLENDOR X and STELLAR M22 are named aesthetic platforms. The Moses 2.0 technology for holmium laser lithotripsy was a notable product development milestone the company has publicly highlighted.

In the surgical laser space, Lumenis competes with companies such as Boston Scientific (which markets the LithoVue and laser lithotripsy portfolio following its acquisition of NxStage and other assets) and Olympus in endourology. In aesthetics, competitors include Cutera, Solta Medical, and Syneron-Candela. The company has historically positioned its holmium laser systems as a reference standard in urological laser lithotripsy, a claim anchored to the Moses pulse-modulation technology.

Lumenis is headquartered in Yokneam Illit in northern Israel, where its core R&D and manufacturing operations are based. Israel is the primary engineering hub for the company, with product development across both the surgical and aesthetic divisions conducted there. The company has been a significant employer in the Yokneam technology corridor for many years.